INT242207

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 5
Disease Relevance 2.82
Pain Relevance 0.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GLP1R) plasma membrane (GLP1R) signal transducer activity (GLP1R)
Anatomy Link Frequency
blood 2
plasma 2
GLP1R (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 3 98.72 Very High Very High Very High
tolerance 15 98.40 Very High Very High Very High
headache 7 5.00 Very Low Very Low Very Low
Inflammation 5 5.00 Very Low Very Low Very Low
Neuropeptide 4 5.00 Very Low Very Low Very Low
potassium channel 2 5.00 Very Low Very Low Very Low
adenocard 2 5.00 Very Low Very Low Very Low
chemokine 2 5.00 Very Low Very Low Very Low
Central nervous system 1 5.00 Very Low Very Low Very Low
rheumatoid arthritis 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 251 99.92 Very High Very High Very High
Impaired Glucose Tolerance 15 98.72 Very High Very High Very High
Hyperglycemia 20 84.40 Quite High
Cardiovascular Disease 53 83.08 Quite High
Hypoglycemia 36 80.12 Quite High
Disease 24 80.08 Quite High
Infection 5 51.64 Quite High
Weight Gain 29 45.12 Quite Low
Prediabetic State 3 39.96 Quite Low
Hyperinsulinism 8 38.72 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Theoretically, DPP-4 inhibition seems to have the strongest potential in early stages of type 2 diabetes because of the impaired GLP-1 secretion in type 2 diabetes, together with both poor insulin secretion and sensitivity as well as partial insensitivity to GLP-1.
Negative_regulation (impaired) of Localization (secretion) of GLP-1 associated with diabetes mellitus
1) Confidence 0.36 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.66 Pain Relevance 0
Some studies have demonstrated a progressive decline in postprandial GLP-1 secretion, where individuals with normal glucose tolerance secrete more than those with impaired glucose tolerance, and individuals with type 2 diabetes demonstrate the greatest impairment in GLP-1 secretion.11 The clinical utility of native GLP-1 is limited by its short half-life (<2 minutes) due to its rapid degradation to inactive metabolites by the enzyme dipeptidyl peptidase-4 (DPP-4).10 Because of this limitation, new treatment approach has been developed to inhibit DPP-4 enzyme and thereby increase endogenous incretin hormone levels.
Negative_regulation (decline) of Localization (secretion) of GLP-1 associated with diabetes mellitus, tolerance and impaired glucose tolerance
2) Confidence 0.33 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2878957 Disease Relevance 0.56 Pain Relevance 0.10
Specifically, it has been demonstrated that the endogenous human incretin hormone GLP-1 decreases blood glucose by several pathways – via the regulation of insulin and glucagon, inhibition of gastric emptying, and suppression of appetite, and that the normal physiologic response to GLP-1 is impaired in type 2 diabetes.9,10,11 GLP-1 stimulates insulin secretion in a glucose-dependent manner and suppresses glucagon secretion.10 In normal physiology, oral ingestion of nutrients stimulates GIP and GLP-1 secretion, which in turn increases insulin secretion from pancreatic beta-cells.
Negative_regulation (suppresses) of Localization (secretion) of GLP-1 in blood associated with diabetes mellitus
3) Confidence 0.33 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2878957 Disease Relevance 0.66 Pain Relevance 0.11
Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes

Type 2 diabetes is associated with decreased incretin hormone response to an oral glucose load, and a progressive decline in postprandial glucagon-like peptide-1 (GLP-1) secretion.

Negative_regulation (decline) of Localization (secretion) of glucagon-like peptide-1 associated with diabetes mellitus
4) Confidence 0.33 Published 2010 Journal Therapeutics and Clinical Risk Management Section Title Doc Link PMC2878957 Disease Relevance 0.29 Pain Relevance 0
GLP-1 secretion may be impaired in T2DM, and GLP-1 analogs and agonists and DPP-4 inhibitors that increase endogenous GLP-1 production have the advantage that their effect on insulin secretion depends on plasma glucose concentration.
Negative_regulation (impaired) of Localization (secretion) of GLP-1 in plasma associated with diabetes mellitus and agonist
5) Confidence 0.09 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515417 Disease Relevance 0.64 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox